Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

Cited In for PubMed (Select 20956803)

1.

Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Chaidos A, Caputo V, Karadimitris A.

Ther Adv Hematol. 2015 Jun;6(3):128-41. doi: 10.1177/2040620715576662. Review.

PMID:
26137204
2.

Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells.

Nadeau MÈ, Rico C, Tsoi M, Vivancos M, Filimon S, Paquet M, Boerboom D.

BMC Cancer. 2015 Jun 24;15:479. doi: 10.1186/s12885-015-1489-1.

3.
4.

Do mantle cell lymphomas have an 'Achilles heel'?

Saba N, Wiestner A.

Curr Opin Hematol. 2014 Jul;21(4):350-7. doi: 10.1097/MOH.0000000000000057.

5.

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, Farooqui M, Wiestner A.

Blood. 2014 May 22;123(21):3286-95. doi: 10.1182/blood-2014-02-548610. Epub 2014 Mar 21.

6.

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.

Cancer Cell. 2013 Sep 9;24(3):289-304. doi: 10.1016/j.ccr.2013.08.009.

7.

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.

Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N.

PLoS One. 2013 Aug 2;8(8):e69126. doi: 10.1371/journal.pone.0069126. Print 2013.

8.

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.

Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.

9.

Molecular pathogenesis of mantle cell lymphoma.

Jares P, Colomer D, Campo E.

J Clin Invest. 2012 Oct;122(10):3416-23. doi: 10.1172/JCI61272. Epub 2012 Oct 1. Review.

10.

Molecular mechanisms of acquired proteasome inhibitor resistance.

Kale AJ, Moore BS.

J Med Chem. 2012 Dec 13;55(23):10317-27. doi: 10.1021/jm300434z. Epub 2012 Oct 3.

11.

Proteasome inhibitors in mantle cell lymphoma.

Holkova B, Grant S.

Best Pract Res Clin Haematol. 2012 Jun;25(2):133-41. doi: 10.1016/j.beha.2012.04.007. Epub 2012 May 16. Review.

12.

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.

Clin Cancer Res. 2012 Apr 1;18(7):1979-91. doi: 10.1158/1078-0432.CCR-11-2113. Epub 2012 Feb 20.

13.

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.

Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N.

Exp Hematol. 2012 Feb;40(2):107-18.e2. doi: 10.1016/j.exphem.2011.10.004. Epub 2011 Oct 21.

14.

New molecular targets in mantle cell lymphoma.

Parekh S, Weniger MA, Wiestner A.

Semin Cancer Biol. 2011 Nov;21(5):335-46. doi: 10.1016/j.semcancer.2011.09.008. Epub 2011 Sep 18. Review.

15.

Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S.

Mol Cancer Ther. 2011 Sep;10(9):1686-97. doi: 10.1158/1535-7163.MCT-10-1108. Epub 2011 Jul 12.

16.

Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy.

Liu Y, Ye Y.

Cell Res. 2011 Jun;21(6):867-83. doi: 10.1038/cr.2011.75. Epub 2011 May 3. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk